Bio-Techne Corp
Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
About
CEO
Mr. Kim Kelderman
Employees
3,100
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
614 McKinley Place N.E., Minneapolis, MN 55413, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 28, 2025 | — | — | — | — |
| Aug 5, 2025 | — | — | — | — |
| Apr 29, 2025 | — | — | — | — |
| Feb 5, 2025 | 0.39 | — | — | — |
| Oct 30, 2024 | 0.38 | 0.42 | 0.04 | 10.53% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Current Year
(Jun 2025)
|
Next Year
(Jun 2026)
|
||
|---|---|---|---|---|
| Number of analysts | — | 11 | 14 | 13 |
| Average estimate | — | 0.51 | 1.89 | 2.19 |
| Low estimate | — | 0.48 | 1.78 | 1.99 |
| High estimate | — | 0.54 | 2.11 | 2.40 |
| Last year EPS | — | 0.48 | 1.77 | 1.89 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-3.670%
Next qtr. (Mar 2025)
7.090%
Current year (Jun 2025)
6.930%
Next year (Jun 2026)
15.920%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total reported revenue | 1.16B | 1.14B | 1.11B | 931.03M | 738.69M |
| Cost of revenue | 389.34M | 366.89M | 349.10M | 298.18M | 255.50M |
| Gross profit | 769.73M | 769.82M | 756.50M | 632.85M | 483.19M |
| Operating expense | |||||
| Research & development | 96.66M | 92.49M | 87.14M | 70.60M | 65.19M |
| Selling general and admin | 396.83M | 352.44M | 339.00M | 289.92M | 240.88M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 242.90M | 291.00M | 295.83M | 242.69M | 148.85M |
| Non operating interest income | |||||
| Income | 3.32M | 3.41M | 794,000 | 473,000 | 605,000 |
| Expense | 15.74M | 11.22M | 11.31M | 13.95M | 19.20M |
| Other income expense | -44.79M | 55.47M | 16.07M | -81.04M | 146.22M |
| Pretax income | 185.69M | 338.66M | 301.39M | 148.18M | 276.48M |
| Tax provision | 17.58M | 53.22M | 38.29M | 8.59M | 47.18M |
| Net income | 168.11M | 285.44M | 263.10M | 139.59M | 229.30M |
| Basic EPS | 1.07 | 1.81 | 1.73 | 0.91 | 1.50 |
| Diluted EPS | 1.05 | 1.76 | 1.66 | 0.87 | 1.46 |
| Basic average shares | 157.71M | 157.18M | 156.88M | 154.99M | 152.80M |
| Diluted average shares | 157.71M | 157.18M | 156.88M | 154.99M | 152.80M |
| EBITDA | 351.42M | 400.97M | 399.15M | 331.81M | 232.54M |
| Net income from continuing op. | 168.11M | 285.44M | 263.10M | 139.59M | 229.30M |
| Minority interests | — | -179,000 | 8.95M | 825,000 | — |
| Preferred stock dividends | 33,000 | 70,000 | 121,000 | 86,000 | 224,000 |
Balance sheet
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 2.70B | 2.64B | 2.29B | 2.26B | 2.03B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 151.79M | 180.57M | 172.57M | 199.09M | 146.63M |
| Other short term investments | 1.07M | 23.74M | 74.46M | 32.46M | 124.27M |
| Accounts receivable | 241.39M | 218.47M | 194.55M | 145.39M | 122.53M |
| Other receivables | — | — | — | — | — |
| Inventory | 179.73M | 171.64M | 141.12M | 116.75M | 103.15M |
| Prepaid assets | — | — | — | — | — |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | 9.77M | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 33.66M | 27.07M | 22.86M | 16.92M | 24.34M |
| Non current assets | |||||
| Properties | 91.29M | 98.33M | 65.56M | 73.83M | 71.47M |
| Land and improvements | 8.15M | 9.10M | 8.57M | 8.61M | 8.52M |
| Machinery furniture equipment | 215.95M | 190.02M | 174.81M | 149.41M | 153.70M |
| Construction in progress | 39.75M | 15.49M | 21.73M | 49.07M | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -256.56M | -233.71M | -211.42M | -189.85M | -169.82M |
| Goodwill | 2.45B | 2.28B | 2.18B | 2.30B | 1.97B |
| Investment properties | — | — | — | — | — |
| Financial assets | 9.81M | 16.86M | — | — | — |
| Intangible assets | 507.08M | 534.65M | 531.52M | 615.97M | 516.55M |
| Investments and advances | 242.34M | 255.86M | — | — | — |
| Other non current assets | 12.12M | 12.59M | 46.83M | 11.58M | 13.52M |
| Total liabilities | 635.02M | 672.18M | 593.79M | 691.72M | 646.40M |
| Current liabilities | |||||
| Accounts payable | 37.97M | 25.68M | 33.87M | 29.38M | 23.09M |
| Accrued expenses | 74.70M | 51.63M | 79.84M | 66.58M | 40.18M |
| Short term debt | 12.92M | 11.20M | 24.43M | 24.10M | 22.04M |
| Deferred revenue | 27.93M | 23.07M | 23.41M | 19.00M | 13.05M |
| Tax payable | 3.71M | 12.02M | 13.24M | 5.34M | 2.38M |
| Pensions | — | — | — | — | — |
| Other current liabilities | 2.15M | 1.41M | 1.24M | 3.89M | — |
| Non current liabilities | |||||
| Long term debt | 406.62M | 443.77M | 301.54M | 396.45M | 411.49M |
| Provision for risks and charges | — | — | 5.00M | 25.40M | 199,000 |
| Deferred liabilities | 55.86M | 88.98M | 98.99M | 93.13M | 101.09M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 13.16M | 10.92M | 12.24M | 24.46M | 26.95M |
| Shareholders equity | |||||
| Common stock | 1.58M | 1.58M | 1.57M | 390,000 | 385,000 |
| Retained earnings | 1.33B | 1.31B | 1.12B | 1.09B | 1.06B |
| Other shareholders equity | -78.32M | -66.06M | -75.20M | -57.29M | -97.20M |
| Total shareholders equity | 2.07B | 1.97B | 1.70B | 1.57B | 1.38B |
| Additional paid in capital | 820.34M | 721.54M | 652.47M | 534.41M | 420.54M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | -759,000 | 8.26M | — |
Cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||||||||
| Net Income | 168.11M | 285.44M | 263.10M | 139.59M | 229.30M | 96.07M | 126.15M | 76.09M | 104.48M | 107.74M | 110.95M | 112.56M | 112.33M | 112.30M | 109.78M | 105.24M | 103.56M | 85.11M | 73.35M | 66.13M | 52.93M | 45.40M | 27.13M | 34.05M | 26.58M | 16.70M | 15.20M | 10.90M | 8.60M | 6.70M | 5.10M | 4.40M | 2.00M | 1.60M | 1.00M |
| Depreciation | 111.71M | 107.24M | 101.07M | 87.75M | 82.74M | 78.17M | 64.46M | 60.04M | 42.76M | 37.23M | 19.18M | 12.32M | 12.47M | 8.70M | 8.13M | 7.77M | 7.26M | 6.99M | 6.96M | 6.11M | 6.04M | 6.35M | 12.69M | 12.74M | 12.65M | 11.90M | 2.30M | 2.30M | 1.90M | 1.70M | 1.80M | 1.30M | 1.00M | 500,000 | 300,000 |
| Deferred Taxes | -39.45M | -29.57M | 6.82M | -27.43M | 13.13M | -13.58M | -46.72M | -3.43M | -2.62M | 1.30M | -2.85M | -2.53M | -7.36M | 3.19M | -1.55M | -730,000 | -661,000 | -797,000 | -937,000 | 672,000 | 317,000 | 232,000 | -6.29M | -508,000 | -1.16M | -1.90M | -400,000 | -700,000 | -1.00M | -200,000 | -800,000 | -100,000 | — | — | — |
| Stock-Based Compensation | 38.04M | 39.23M | 42.18M | 48.98M | 32.37M | 32.28M | 28.24M | 14.63M | 9.43M | 5.96M | 3.52M | 1.86M | 1.64M | 1.14M | 1.14M | 1.48M | 1.73M | 1.58M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | -479,000 | -9.19M | -22.64M | 6.14M | -9.54M | 4.06M | -3.27M | 11.85M | 5.15M | 6.80M | 8.07M | 5.26M | 7.80M | 2.06M | 222,000 | 458,000 | 1.60M | 168,000 | -6.23M | — | — | — | — | — | — | -100,000 | -100,000 | 100,000 | 1.20M | 300,000 | 300,000 | -100,000 | -100,000 | 200,000 | — |
| Accounts Receivable | -20.53M | -20.87M | -57.60M | -15.55M | 6.56M | -15.00M | -2.70M | -19.69M | -22.98M | -11.75M | 1.15M | -2.33M | -2.10M | -3.62M | -4.03M | 49,000 | -1.72M | -5.00M | -2.15M | -1.03M | -1.17M | -638,000 | -855,339 | -3.04M | -2.14M | -3.80M | -1.00M | -600,000 | -1.20M | -800,000 | -400,000 | -1.60M | -800,000 | -400,000 | -400,000 |
| Accounts Payable | 25.77M | -7.91M | 12.74M | 19.09M | 10.34M | 6.10M | 5.03M | 5.70M | 8.92M | 2.15M | 1.37M | 243,000 | 1.58M | -591,000 | -74,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -14.22M | -30.17M | -32.01M | -7.14M | -14.86M | -13.65M | -13.33M | -732,000 | -6.63M | -4.71M | -2.90M | -2.22M | -1.58M | 3.68M | -2.37M | -4.93M | 8.80M | 2.82M | 13.77M | 1.94M | 3.92M | 12.76M | -4.41M | 5.23M | 6.11M | 5.20M | 1.80M | 100,000 | -100,000 | -700,000 | 200,000 | 500,000 | 1.10M | -100,000 | — |
| Operating Cash Flow | 268.95M | 334.22M | 313.67M | 251.42M | 350.03M | 174.46M | 157.87M | 144.45M | 138.52M | 144.72M | 138.48M | 125.17M | 124.79M | 126.86M | 111.24M | 109.34M | 120.57M | 90.86M | 84.75M | 73.82M | 62.03M | 64.11M | 28.26M | 48.47M | 42.04M | 28.00M | 17.80M | 12.10M | 9.40M | 7.00M | 6.20M | 4.40M | 3.20M | 1.80M | 900,000 |
| Investing Activities | |||||||||||||||||||||||||||||||||||
| Capital Expenditures | -62.88M | -38.24M | -44.91M | -44.30M | -51.74M | -25.41M | -20.93M | -15.18M | -16.90M | -19.91M | -13.82M | -22.45M | -6.02M | -3.63M | -4.64M | -6.56M | -16.37M | -8.08M | -4.60M | -11.41M | -3.71M | -15.19M | -22.28M | -6.81M | -30.37M | -30.60M | -2.60M | -4.20M | -6.40M | -1.30M | -1.30M | -2.60M | 400,000 | -900,000 | -400,000 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | -169.71M | -83.36M | — | -225.91M | 1.91M | -289.49M | -46.28M | -293.79M | -91.42M | -420.10M | -119.18M | — | — | -131.77M | 50,000 | — | — | — | -19.59M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -5.53M | -20.50M | -78.00M | -39.68M | -70.19M | -43.48M | -8.57M | -3.07M | — | — | -106.75M | -112.71M | -147.01M | -151.37M | -176.62M | -49.17M | -79.31M | -57.31M | -104.74M | -146.87M | -144.23M | -64.56M | -64.68M | -57.18M | -39.57M | -15.00M | -24.20M | -16.00M | -11.90M | -10.40M | -4.70M | -5.50M | -1.90M | — | — |
| Sale of Investments | 28.08M | 108.46M | 26.06M | 66.38M | 147.12M | 21.58M | 36.39M | 6.08M | 776,000 | 13.47M | 289.41M | 103.61M | 131.73M | 173.52M | 66.60M | 75.67M | 68.97M | 25.59M | 58.21M | 212.02M | 96.90M | 58.05M | 69.81M | 23.84M | 13.45M | 14.00M | 25.00M | 11.60M | 10.70M | 4.90M | 3.40M | 3.00M | 500,000 | — | — |
| Investing Cash Flow | -210.03M | -33.65M | -96.85M | -243.52M | 27.10M | -336.80M | -38.71M | -305.95M | -107.57M | -426.49M | 49.69M | -31.20M | -21.67M | -114.19M | -114.57M | 21.28M | -27.51M | -39.92M | -70.72M | 53.28M | -59.51M | -21.71M | -22.40M | -40.65M | -60.04M | -38.60M | -4.10M | -8.80M | -7.60M | -7.40M | -4.40M | -5.10M | -1.00M | -900,000 | -400,000 |
| Financing Activities | |||||||||||||||||||||||||||||||||||
| Long-Term Debt Issuance | 225.00M | 619.66M | 90.00M | — | 40.00M | 580.00M | 55.00M | 368.50M | 77.00M | 163.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -256.00M | -525.66M | -175.50M | -271.50M | -188.50M | -413.50M | -59.50M | -116.50M | -58.50M | -94.96M | — | — | — | — | — | — | — | -13.43M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -21.87M | -31.35M | -23.37M | -19.34M | -7.27M | -6.30M | -65.89M | -20.82M | 279,000 | 615,000 | 262,000 | 75,000 | 51,000 | 847,000 | 196,000 | 107,000 | 524,000 | 534,000 | 7.99M | — | — | — | — | — | — | — | — | — | — | — | — | -100,000 | — | -100,000 | — |
| Financing Cash Flow | -183.33M | 612.46M | -405.51M | -127.64M | -403.29M | 262.93M | -122.86M | 435.86M | -10.33M | 89.58M | -45.13M | -45.78M | -65.47M | -41.08M | -50.51M | -119.44M | -56.59M | -11.38M | -6.73M | -95.92M | 4.09M | -21.22M | -413,442 | -348,876 | 6.47M | -2.80M | 600,000 | -2.60M | -100,000 | -400,000 | — | 100,000 | 100,000 | — | -200,000 |
| Other Cash Details | |||||||||||||||||||||||||||||||||||
| End Cash Position | 151.79M | 180.57M | 172.57M | 199.09M | 146.63M | 100.89M | 121.99M | 91.61M | 64.24M | 54.53M | 318.57M | 163.79M | 116.68M | 77.61M | 94.14M | 160.94M | 166.99M | 135.49M | 89.63M | 80.34M | 51.20M | 39.37M | 26.39M | 21.27M | 17.36M | 12.80M | 26.10M | 8.60M | — | — | — | — | — | — | — |
| Income Tax Paid | 65.25M | 88.43M | 30.34M | 20.95M | 41.99M | 36.81M | 35.08M | 42.90M | 44.90M | 42.60M | 55.20M | 51.60M | 58.70M | 46.20M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 14.50M | 8.37M | 11.03M | 13.58M | 18.62M | 21.50M | 9.84M | 7.45M | 1.66M | 1.54M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 236.10M | 216.15M | 280.36M | 307.86M | 153.47M | 156.21M | 149.43M | 128.54M | 127.26M | 119.45M | 122.94M | 101.11M | 120.73M | 123.56M | 106.62M | 104.77M | 98.95M | 82.43M | 80.99M | 63.02M | 61.84M | 40.04M | 5.39M | 39.56M | 8.37M | -2.20M | 18.10M | 8.30M | 3.40M | 6.00M | 5.00M | 1.90M | 3.30M | 900,000 | 700,000 |
Error: Invalid format in Holders JSON file.
Article
EXEL or TECH: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Feb 6, 2025
Article
Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment.
Feb 5, 2025
Article
Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH ) Q2 2025 Earnings Conference Call February 5, 2025 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President and Chief Executive Officer Jim Hippel - Executive Vice President and Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Dan Leonard - UBS Matt Larew - William Blair Catherine Schulte - Baird Dan Arias - Stifel Conor McNamara - RBC Patrick Donnelly - Citi Sung Ji Nam - Scotiabank Operator Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will be open for questions following management's prepared remarks.
Feb 5, 2025
